Applying Cancer Knowledge to COVID Vaccine Research

Segment Description: Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio, explains why the firm's COVID-19 research benefits from drawing on a background in cancer.

Part 1: SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Part 2: Goals of Operation Warp Speed

Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, describes goals and expectations for the accelerated coronavirus vaccine program Operation Warp Speed.

Part 3: Justice & American Values During the Coronavirus Pandemic

Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, discusses the pandemic as a unique moment in world & American history.